STENOCARE A/S: Notice for deadline of trading TO2 Warrants

Report this content

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

Stenocare TO2 Warrant trading will end close of business June 19. To benefit from the discounted share price of DKK 3.16 each, subscribers need to own TO2 Warrants (ticker: STENO TO2).

Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. These warrants can be purchased and/or sold until the deadline of June 19, 2024, at 17:00 Central European Summer Time.

The TO2 Warrants can be used to subscribe to (purchase) the new Stenocare shares at a discounted price of DKK 3.16 each during the exercise period from June 10 to June 21. TO2 Warrant owners who decide to subscribe before this deadline must instruct their bank to exercise (use) the TO2 Warrants.

Please note that TO2 Warrants not exercised (used) before June 21 will be void and cannot be traded after the deadline.

The investment brochure

To inform existing shareholders of Stenocare and other investors and stakeholders about the exercise of TO2 warrants, an investment brochure has been prepared. This brochure contains details about the Company, its business, products and strategy. Information is also available on the investor website of Stenocare https://stenocare.com/share-issue-to2-2024/

On the Stenocare Facebook wall, there are also two 15 minutes interviews with Proinvestor.com and STOKK.IO – that provide more information about the TO2 Warrant and the company: https://www.facebook.com/stenocare

The summary

Summarized terms for the warrants of series TO2:

  • Exercise price: 3.16 DKK per share – ticker: [STENO TO 2] / ISIN DK0062493615
  • Exercise period: 10 June 2024 – 21 June 2024 (both days included)
  • Last day of trading warrants of series TO2: 19 June 2024
  • Issue volume: 1,712,999 warrants of series TO2
  • Dilution: Up to 8.5 percent

For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO          Phone: +45 31770060            E-mail: presse@stenocare.com

About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark.

www.stenocare.com    www.stenocare.dk